Uncategorized

Who would argue that we don't need innovation in biopharmaceuticals? Some are even calling for disruptive innovation, to tackle the thorny issues of affordability and availability of new medical products.…

PharmaFlow is pleased to announce that highly experienced EU QP David Franks has agreed to join the PharmaFlow core team of independent experts. Below is a roundup of David's background:…

The answer is 'far less than you would think!' In this STAT article Letting academic medical centers make CAR-T drugs would save billions, medical centres in the US, and their…